Mineralys Therapeutics Inc. (MLYS)
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MLYS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.21B
- EPS (TTM)
- -$4.30
- Dividend yield
- None
- 52-week range
- 13.57 – 44.13
- Day range
- 13.57 – 14.79
- Volume / Avg
- 1.35M / 1.55M
- Beta
- —
- Shares outstanding
- 88.56M
52-week range
MLYS stock today
Shares of Mineralys Therapeutics (MLYS) finished lower on Nov 20 at $13.66, a drop of 3.53% or $0.50 per share, versus the S&P 500's 3.70% decline. Shares are 69.0% below their 52-week high of $44.13, set on Nov 26, 2025 and 0.7% above the 52-week low of $13.57, near the bottom of the past year's range. MLYS is down 62.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.4%.
Mineralys Therapeutics has posted a net loss over the last twelve months (EPS of -$4.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mineralys Therapeutics
Company profileMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jon Congleton
- Headquarters
- Radnor, PA
- Employees
- 76
- IPO year
- 2023
- Website
- mineralystx.com
Financial highlights
Full financialsMineralys Therapeutics reported a net loss of $154.7 million, compared with a loss of $177.8 million a year earlier. Diluted earnings per share came in at -$2.29.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-154.65M | $-177.81M | $-71.90M | $-29.80M |
| EPS (diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$43.56+218.89%
- Strong buy 0
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.64 vs $-0.53
- Surprise
- -20.75%
MLYS news
All MLYS news- Why is Mineralys Therapeutics stock climbing today?Investing.com
- Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026GlobeNewswire
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNasdaq
- Mineralys Therapeutics GAAP EPS of -$0.64 misses by $0.09Seeking Alpha
- Mineralys Therapeutics, Inc. Terminates License Agreement and Acquires Lorundrostat IP from Tanabe PharmaNasdaq
- Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026GlobeNewswire
- Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney DiseaseNasdaqMLYS, SUN
Mineralys Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs MLYS |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs MLYS |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs MLYS |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs MLYS |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs MLYS |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs MLYS |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs MLYS |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs MLYS |
Indexes, lists and sector
Mineralys Therapeutics stock FAQ
What is Mineralys Therapeutics's stock price today?
MLYS last traded at $13.66 as of Nov 20, 4:00 PM EST, down 3.53% on the day. Prices are delayed at least 15 minutes.
Who is Mineralys Therapeutics's CEO?
Dr. Jon Congleton is the chief executive officer of Mineralys Therapeutics Inc., which has about 76 employees.
What is the MLYS 52-week high?
The 52-week high for MLYS is $44.13 and the 52-week low is $13.57. The stock is currently 69.0% below its high.